33 results about "Bacillus anthracis spore" patented technology

Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis having a variant of recombinant Bacillus anthracis protective antigen (rPA) and a variant of recombinant Bacillus anthracis lethal factor (rLF). These proteins may be expressed separately or as a fusion protein. The recombinant proteins are produced in an avirulent strain of Bacillus anthracis that overproduces the desired antigens. The compositions and methods induce the animal host to produce antibodies against a virulent strain of Bacillus anthracis.

Vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery are provided. The invention provides edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis.

The present invention pertains to the discovery that B. anthracis possesses a luxS gene that encodes a functional LuxS polypeptide, and that B. anthracis synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant B. anthracis bacteria lacking the function of the luxS gene, which do not produce a functional AI-2 molecule and have growth defects compared to wild-type B. anthracis. The invention also concerns methods for inhibiting the growth of B. anthracis, or for preventing or treating B. anthracis infection, by inhibiting the activity of the B. anthracis LuxS polypeptide, or by exposure of the B. anthracis to furanone. In particular, the invention concerns the use of furanone, a compound that inhibits AI-2-mediated quorum-sensing, to inhibit the growth of B. anthracis, to inhibit B. anthracis toxin production, particularly that of protective antigen, and to prevent or treat B. anthracis infection. The invention also provides methods to prevent B. anthracis infection, or enhance an immune response to B. anthracis infection, by administering a vaccine comprising a B. anthracis cell in which the luxS gene is mutated.

The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.

Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus anthracis. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.

A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.

The present invention pertains to the discovery that B. anthracis possesses a luxS gene that encodes a functional LuxS polypeptide, and that B. anthracis synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant B. anthracis bacteria lacking the function of the luxS gene, which do not produce a functional AI-2 molecule and have growth defects compared to wild-type B. anthracis. The invention also concerns methods for inhibiting the growth of B. anthracis, or for preventing or treating B. anthracis infection, by inhibiting the activity of the B. anthracis LuxS polypeptide, or by exposure of the B. anthracis to furanone. In particular, the invention concerns the use of furanone, a compound that inhibits AI-2-mediated quorum-sensing, to inhibit the growth of B. anthracis, to inhibit B. anthracis toxin production, particularly that of protective antigen, and to prevent or treat B. anthracis infection. The invention also provides methods to prevent B. anthracis infection, or enhance an immune response to B. anthracis infection, by administering a vaccine comprising a B. anthracis cell in which the luxS gene is mutated.

The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and / or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

The invention includes compositions and methods of detection of Bacillus anthracis that use oligonucleotide probes specific for genetic material contained in the pXO1 and pXO2 plasmids in nucleic acid hybridization reactions. Embodiments of the method may include additional probes specific for other gene sequences to distinguish B. anthracis from other bacterial species present in a sample or to provide an indication that the assay was performed properly even when no Bacillus sequence is detected.

The invention relates to the technical fields of animal bacteriology and zoonosis science, particularly to an application of a dominant inhibitory mutant F427D as an inhibitor of Bacillus anthracis toxin and an application of vaccine thereof. The invention, through cloning of Bacillus anthracis lethal toxin gene, expression and purification of proteins, site-directed saturation mutagenesis of genes and the like, obtains protective antigen (namely the dominant inhibitory mutant F427D) of the Bacillus anthracis, the mutant is successfully cloned into pronucleus expression carrier pGEX-KG and composes recomposed plasmid pGEX-KG-PA (F427D). Escherichia coli containing the recomposed plasmid is nominated as Escherichia coli DH5Alpha / pGEX-KG-PA (F427D) and collected in the China Center for TypeCulture Collection with a collection number of CCTCC-M208158. The invention further discloses the method for preparing the antigen protein, the preparation of anthrax toxin inhibitor and subunit vaccine by using the antigen protein and the application thereof.

The present invention relates to conjugates of oligosaccharides of formula 1, wherein R is a linker to a carrier protein and optionally comprises up to three further saccharides, 5 and which are useful for vaccination, methods of synthesis of such conjugates, antibodies against this antigen, hybridoma producing monoclonal antibodies against this antigen, assays using these antibodies for the detection of B. anthracis spores and kits comprising these antibodies, and a vaccine for the prevention of B. anthracis infection comprising the conjugates of oligosaccharides of formula 1. Monoclonal antibodies 10 according to the invention selectively bind to B. anthracis, but not to related bacteria such as B. subtilis, B. cereus and other bacteria of this group such as B. thuringiensis.

Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.

The drug has a bactericidal effect on vegetative and spore cells of Bacillus anthracis and comprises a bacteriolytic complex produced by Lysobacter sp. XL 1. The bacteriolytic complex produced by is in a method of anthrax prevention and treatment.